(A) TIC overlay of pegfilgrastim main peak and Pre-peak impurity (RRT 0.84) in peptide mapping (10–75 min) (B) TIC overlay of pegfilgrastim main peak and Pre-peak impurity (RRT 0.84) in peptide mapping (75–145 min).</p
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
(A) TIC overlay of pegfilgrastim main peak and Pre-peak impurity 1 (RRT 0.60) in peptide mapping (10...
(A) Representative RP-HPLC profile of stressed deamidated INTP5 (Sample I2) for peak collection. (Hi...
(A) Representative RP-HPLC profile of oxidized (24 hours) INTP5 Sample I2 (B) Overlay of control sam...
The approval of biosimilars requires demonstration of biosimilarity, which rests on the base of thor...
(A) Overlay of far UV CD spectra, (B) Overlay of FTIR spectra, (C) Overlay of fluorescence spectra, ...
The approval of biosimilars requires demonstration of biosimilarity, which rests on the base of thor...
(A) Overlay of RP chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4 and E...
(A) Overlay of SEC-HPLC chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4...
(A) Dose response profile of in vitro cell proliferation assay; (B) Dose response profile of recepto...
(A) Overlay of CEx chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4 and ...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
(A) TIC overlay of pegfilgrastim main peak and Pre-peak impurity 1 (RRT 0.60) in peptide mapping (10...
(A) Representative RP-HPLC profile of stressed deamidated INTP5 (Sample I2) for peak collection. (Hi...
(A) Representative RP-HPLC profile of oxidized (24 hours) INTP5 Sample I2 (B) Overlay of control sam...
The approval of biosimilars requires demonstration of biosimilarity, which rests on the base of thor...
(A) Overlay of far UV CD spectra, (B) Overlay of FTIR spectra, (C) Overlay of fluorescence spectra, ...
The approval of biosimilars requires demonstration of biosimilarity, which rests on the base of thor...
(A) Overlay of RP chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4 and E...
(A) Overlay of SEC-HPLC chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4...
(A) Dose response profile of in vitro cell proliferation assay; (B) Dose response profile of recepto...
(A) Overlay of CEx chromatographic profile of INTP5, US Neulasta and EU Neulasta (Sample I2, U4 and ...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...
Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutr...